Tuesday, May 26, 2020
The FDA last week approved...
...AstraZeneca and Merck's Lynparza
for use in some treatment-resistant prostate cancers — the PARP inhibitor's
fourth oncology nod. For the treatment of triple-negative breast cancer,
Lynparza currently holds preferred status for 4% of covered lives under the
pharmacy benefit, growing to 41% with prior authorization and/or step therapy.
SOURCE: MMIT Analytics, as
of 5/20/20
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment